Foralumab stabilized disability for 6 months in all 10 people with nonactive SPMS who took part in an expanded access program, a study found.

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

Brenig has launched an early Phase 1 trial to evaluate BT-409, its experimental small molecule therapy, in healthy volunteers ...

Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...

Immediately after occupational therapy (OT), people with multiple sclerosis may show small improvements in daily functioning and mental health-related quality of life (HR-QoL), but OT may have little ...

The therapeutic landscape for multiple sclerosis (MS) is evolving beyond modulating the peripheral immune response. New strategies are now focussed on reducing inflammation and promoting the ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

A stem cell treatment commonly used for blood cancer appears effective in treating one form of MS The treatment has been available since the 1990s but questions about safety and difficulty have ...

Dr. Carolyn Phillips has developed a therapeutic program for patients that integrates music — specifically, the ukulele — to help with movement and memory.